Jeffrey Schouten, MD, JD, AAHIVE is Director of the Office of HIV/AIDS Network Coordination (HANC) at the Fred Hutchinson Cancer Research Center. As HANC Director he provides leadership and strategic direction for all of the cross-network coordination activities that the HANC project encompasses. The Director works closely with the Network Leaders and the Division of AIDS (DAIDS) of the NIH to develop and implement strategies to coordinate activities and optimize collaboration between the networks and DAIDS and other funding and operational partners. The networks include the AIDS Clinical Trials Group (ACTG), the HIV Prevention Trials Network (HPTN), the HIV Vaccine Trials Network (HVTN), the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) and the Microbicide Trials Network (MTN). Jeff has been the HANC Director since September 2008. He is also a Clinical Associate Professor in the Surgery Department and Allergy and Infectious Diseases Divisions of the University Of Washington School Of Medicine and a senior staff scientist at the Fred Hutchinson Cancer Research Center. He is an attending physician at the Madison Clinic at Harborview Medical Center and founded the Anal Dysplasia Clinic at Harborview in February 2012. He is certified to perform high resolution anoscopy by the AIDS Malignancy Consortium for their research trials and performs infrared coagulation ablation of high grade anal dysplasia as well. He is a former general surgeon with a focus on surgical oncology. He has been involved in HIV clinical research and HIV primary care for more than two decades. As a co-investigator at the University of Washington AIDS Clinical Trials Unit since 2002, he has served as local PI on many protocols, on many international protocol teams as an investigator and as a vice-chair on two protocols (A5200 and A5271), as well as several terms on ACTG scientific review committees, most recently the Optimization of Co-Infection and Co-Morbidity Management Committee. Jeff has had a long commitment to HIV clinical research, complications of HIV treatment and the new high priority area of eradication or functional cure of HIV.
Krishnan S, Schouten JT, Atkinson B, Brown TT, Wohl D, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Jacobson DL. Changes in metabolic syndrome status after initiation of antiretroviral therapy . J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):73-80. PMCID: PMC4262682 [Available on 2016/1/1].
Schouten JT, Schiffer JT. Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2012; 60(1): 68-71.
Rosas SR, Kagan JM, Schouten JT, Slack PA, Trochim WM. Evaluating research and impact: A bibliometric analysis of research by the NIH/NIAID HIV/AIDS clinical trials networks. PLoS One. 2011; 6(3): e17428.
•PLoS One Abstract
Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, Smurzynski M, Bosch RJ, Bastow B, Schouten JT. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011; 52(7): 929-40.
Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, Santana J, Sattler FR, Mitsuyasu R. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudenal linked randomized trials analysis. Oncology. 2011; 80(1-2): 42-9.
Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis. 2010; 50(5): 787-91.
Heath L, Fox A, McClure J, Diem K, van 't Wout AB, Zhao H, Park DR, Schouten JT, Twigg HL, Corey L, Mullins JI, Mittler JE. Evidence for limited genetic compartmentalization of HIV-1 between lung and blood. PLoS One. 2009; 4(9): e6949.
• PubMed Abstract